More Americans now smoke weed daily than drink incase the law hasn’t noticed.
Your Saturday recap of the seven days that moved cannabis: insurers warming to reimbursement, Delaware greenlighting THC drinks, and a former AG reopening the “no medical value” fight the government a
Somewhere in Colorado, an insurance company spent a year quietly paying for one chronic-pain patient’s medical marijuana, and by the end of it the guy had cut his opioid use, come off both drugs entirely, and started moving around better than he had in years. An insurer covered weed, and the math worked out in its favor. Sit with that for a second, because it tells you almost everything about where this industry actually stands right now.
The market has completely made up its mind about cannabis. More Americans use it daily than drink alcohol daily. People are grabbing THC seltzers instead of beer. Patients are managing real pain with it whether or not their doctor will say the word out loud. That argument is finished, and cannabis won it walking away.
The institutions are another story. Insurers are only now cautiously running the numbers. Congress still can’t decide which hemp products get to survive past November. A former U.S. attorney general spent this week insisting cannabis has no medical value, seemingly without checking with his own government first. That’s the story of the week, and honestly of the year: the customers moved on, and the rulebook is still parked where it was in 2016, blinking in the sunlight. Here are the eight stories that show just how wide the gap has gotten.
Workers’ comp might be medical cannabis’s next big breakthrough.
That Colorado story from up top is a real pilot program. e state followed one carefully screened chronic-pain patient for a year, covering non-inhalable medical marijuana, and reported lower pain, better mobility, no adverse events, a 17% drop in monthly opioid use, and eventually the patient stopping both opioids and THC altogether.
It’s one patient, so let’s not oversell it. This proves nothing broad about clinical effectiveness on its own. But it demonstrates the exact thing insurers have always been skeptical about, that cannabis can actually be tracked, reimbursed, and built into a structured care plan like any other covered treatment. And that’s a big deal, because workers’ comp lives and dies on cost containment. A chronic workplace injury can mean years of doctor visits, prescriptions, disability payments, and settlement exposure. If cannabis helps even a chunk of those patients function better or lean on pricier medications less, insurers start seeing coverage as smart claims management instead of a political favor.
An insurer didn’t cover cannabis because it went soft on weed. It covered cannabis because the spreadsheet said to. That’s a far more durable reason.
The catch for operators is that reimbursement raises the bar hard. Insurers will expect consistent products, clear dosing, reliable labeling, and documentation that survives utilization review, which is a level of rigor a lot of the industry isn’t built for yet.
The bottom line: Medical cannabis may earn its strongest legitimacy the day insurers decide it delivers better outcomes at lower total cost. That’s a numbers argument, not a culture-war one.
William Barr is reopening the “no medical value” fight, and accidentally revealing the real motive.
Former Attorney General William Barr, writing with Smart Approaches to Marijuana CEO Kevin Sabet, is arguing cannabis has no proven medical value and shouldn’t move to Schedule III. He also warned that rescheduling would hand cannabis businesses a big tax break by removing 280E.
That second part is the tell. Notice the argument isn’t purely about public health anymore. There’s now open worry that rescheduling would make cannabis businesses financially stronger, which is a very different objection than “this hurts people,” and it quietly reframes what the opposition is actually protecting.
When the argument shifts from “it’s dangerous” to “it’ll help their tax bill,” you’re not hearing a health concern anymore. You’re hearing a business one.
Meanwhile the government’s own review points the other way. Federal health officials already concluded marijuana has accepted medical use, and federal testimony keeps stressing its therapeutic potential and its relative safety next to alcohol and opioids. There’s a legitimate scientific debate to be had about standardization and dosing and the gap between raw cannabis and FDA-approved medicine, and I won’t wave that away. But Schedule I doesn’t mean “lacks FDA approval.” It means no accepted medical use, period, and that gets awfully hard to defend when state programs serve millions of patients and government-funded studies keep documenting benefits.
The bottom line: The rescheduling fight is now about medicine, taxes, and market power all at once, not just which schedule a drug sits in.
Delaware built a legal lane for THC drinks, with a ticking clock attached.
Delaware picked regulation over prohibition for hemp-derived THC beverages, limiting sales to 21-plus with potency caps, testing, packaging rules, and taxes. Single-serving drinks can hit 10mg of THC, larger packages more, sold through licensed liquor stores and dispensaries.
Slotting THC beverages between the cannabis and alcohol worlds is smart, and it could expand distribution in a serious way, since liquor stores already have age verification, cold storage, and steady foot traffic. There’s a tradeoff baked in, since it favors established retailers while shutting out the convenience stores and wellness shops that used to sell hemp. But the real danger here is federal, and it’s a serious one. Delaware’s market has a sunset provision tied to the federal hemp definition. If that November restriction lands as written, much of what Delaware just legalized could become federally unlawful within months.
Delaware is inviting companies into a legal market and quietly handing them an expiration date. Launch now, and Washington might shut you down before you break even.
The bottom line: Delaware built a credible THC-beverage framework, but the November federal deadline could erase the category before anyone makes their money back.
New York’s wage fight exposes a much bigger market problem.
New York operators are asking Governor Hochul to veto a bill creating a dedicated wage board for cannabis workers, which would study pay across cultivation, processing, retail, delivery, and distribution and recommend minimum wages for each.
Here’s what makes this hard: both sides are right. Supporters say cannabis workers deserve fair pay in an industry that loves to brand itself as progressive. Fair. Operators say the timing could break businesses already drowning in delayed licensing, expensive capital, heavy compliance costs, and competition from unlicensed stores that follow none of these rules. Also fair. Workers shouldn’t have to subsidize a legal market with low wages, but legal businesses can’t absorb unlimited costs while illegal competitors skip taxes, labor rules, and licensing fees entirely.
The real problem isn’t wages versus survival. It’s that you can’t set fair pay in a market that hasn’t fixed its own broken economics first.
The actual issue underneath both positions is coordination. You can’t design wage standards sealed off from tax policy, enforcement, financing, and licensing reform, and expect it to hold.
The bottom line: Fair wages and operator survival aren’t enemies. But New York can’t fix pay while ignoring the broken market around it, or it just moves the pain somewhere else.
Congress has yet another hemp rescue bill, and still no actual answer.
A new congressional proposal would delay the federal hemp crackdown and swap the uncertainty for national product standards, banning sales under 21, requiring domestic production, limiting products to naturally occurring cannabinoids, and mandating lab testing, child-resistant packaging, manufacturing standards, and QR codes linked to results.
The encouraging part is what it signals. The debate has shifted from “should hemp THC be legal at all” to “what rules should it follow,” and lawmakers increasingly agree the category needs age limits, testing, and real manufacturing standards. But the problem is fragmentation. There are now several competing bills, and White House support is uneven depending on the product category.
A circulated draft is not a law. It’s a Word document with ambition. It doesn’t make payroll and it doesn’t survive a committee markup.
Farmers, manufacturers, lenders, and retailers cannot build real plans around legislative momentum, because momentum doesn’t pay the bills. Until something actually passes, November is still the only date that matters.
The bottom line: Congress looks like it’s drifting toward regulation instead of prohibition, which is good, but the industry still faces a hard November deadline with no final law in hand.
More Americans now use cannabis daily than drink daily. Let that sink in.
Federal data shows daily or near-daily marijuana use now tops comparable alcohol and cigarette use. Roughly 21.4 million Americans reported using cannabis on at least 20 of the past 30 days, versus 17.2 million near-daily drinkers and 19.9 million daily cigarette smokers.
I want to be careful, because this cuts a couple ways. It does not mean cannabis is harmless. What it clearly means is that federal law has drifted way out of step with how Americans actually live.
Cannabis is still federally restricted while more people use it daily than drink daily. The law isn’t protecting the public from a fringe habit anymore. It’s out of sync with a mainstream one.
For operators, the data confirms what you already sense, that repeat customers are the backbone of the business. But I’d flag the harder question underneath, because alcohol and tobacco offer a real warning: companies can get dangerously dependent on their heaviest users. There’s a genuine public-health conversation to be had about dependency, potency, and marketing, and the smart long-term play is showing that growth doesn’t require encouraging problematic use.
The bottom line: Cannabis is already mainstream in how people actually behave. The legal framework just hasn’t caught up to its own citizens.
Hemp bans don’t kill demand. They just reroute it.
When states restrict hemp-derived THC products, a lot of consumers don’t quit, they move into the licensed marijuana market instead. A recent survey found half of affected consumers got medical marijuana cards, while others started buying from dispensaries.
On the surface that’s a win for state cannabis operators. But it raises an uncomfortable question worth asking out loud: are hemp bans really about public health, or partly about shielding licensed marijuana markets from cheaper competition? State cannabis businesses carry higher taxes, tighter licensing, and heavier compliance, while hemp products often reach shoppers through cheaper, more convenient channels. From the operator’s chair, that looks like unfair competition. From the consumer’s chair, hemp is just more accessible, especially in rural areas or states with thin medical programs. And there’s a catch that should give ban-happy states pause, since the survey found some consumers hit access problems after restrictions. In places without a solid legal alternative, a ban pushes people to unregulated sellers, not dispensaries.
You can win the policy fight and still lose the actual goal, sending demand straight into the illicit market you claimed to be worried about.
The bottom line: Hemp restrictions shuffle consumers between markets. They don’t reduce demand, and sometimes they hand it to the worst possible channel.
Sky-high cannabis taxes are quietly funding the illicit market.
A federally funded study found that when legal cannabis prices climb, a lot of consumers don’t cut back, they switch to illicit sellers. That one finding should reshape how lawmakers think about cannabis taxes.
States love stacking excise, sales, and local taxes on regulated marijuana. But legal operators are competing against dealers who pay none of it, so every extra layer of tax widens the gap between legal and illegal products. And that gap hits all the way down the chain: weaker sales and squeezed margins for retailers, oversupply and collapsing prices for cultivators, distressed borrowers and tenants for lenders and landlords. One tax decision, felt everywhere.
Cannabis is not a captive market. Tax legal weed like buyers have nowhere else to go, and they’ll cheerfully prove you wrong by calling their old dealer.
To be clear, the answer isn’t zero taxes. Legal markets genuinely need enforcement, labs, regulators, and education, and that costs money. But governments have to internalize one basic fact they keep forgetting: consumers have alternatives, and they’ll use them.
The bottom line: The illicit market is a pricing competitor, not a defeated one. States can’t tax legal cannabis like consumers have no other option, because they do.
📊 Weekend Poll
Weekend closing
This week told one clear story from a dozen angles: the market already moved, and the institutions are still lagging behind.
Patients are managing pain with cannabis. Consumers are picking THC drinks over alcohol. Millions use marijuana daily. States are building real systems around products federal law still treats as exceptional. And across the gap, insurers are only just starting to study reimbursement, Congress is still arguing over which hemp products live or die, New York is weighing wage rules inside a market that hasn’t solved illicit competition, and Delaware is authorizing THC drinks while openly admitting the feds might wipe them out.
That lag is the defining problem of cannabis policy right now. Businesses are told to operate like normal companies while facing abnormal taxes, financing walls, and legal limbo. Workers are told to accept instability while waiting on fair standards. Consumers are told to buy regulated products even when taxes make the illegal option meaningfully cheaper. None of it holds up for long.
A mature cannabis policy has to do more than allow sales. It needs insurance rules that reflect the clinical evidence, taxes that keep legal businesses competitive, labor standards fragile companies can actually bear, and hemp regulation that separates responsible manufacturers from bad actors. Cannabis isn’t asking to be recognized as part of the economy anymore. It already is part of the economy. The only open question is whether the rules will finally catch up.
That’s the real weekend takeaway. The market normalized. Policy is still playing catch-up.
That’s what this newsletter is for.
What’s the biggest regulatory challenge your operation is facing right now? Hit reply, I read every response and it shapes what I cover next week.
If this was useful, forward it to someone in the cannabis space or hit the restack button on Substack. It’s how this community grows.